Expertise in
7
conditions

Dr. Ifeyinwa Osunkwo

Hematology | Oncology
Office
1021 Morehead Medical Dr, 
Charlotte, NC 
Expertise in
7
conditions
Office
1021 Morehead Medical Dr, 
Charlotte, NC 

Overview

Ifeyinwa Osunkwo is a Hematologist and an Oncologist practicing medicine in Charlotte, North Carolina.

Dr. Osunkwo is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, and Hemolytic Anemia.

She is actively involved in clinical research, co-authoring 46 peer reviewed articles and participating in 7 clinical trials.

Specialties

Hematology
Oncology

Licenses

Pediatrics in NC

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

Office
1021 Morehead Medical Dr, Charlotte, NC 28204

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab Versus Placebo, With or Without Hydroxyurea/ Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients With Vaso-Occlusive Crises (STAND)
A Phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab Versus Placebo, With or Without Hydroxyurea/ Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients With Vaso-Occlusive Crises (STAND)
Enrollment Status: Active_not_recruiting
Publish Date: April 01, 2026
Intervention Type: Drug
Study Drug: Crizanlizumab
Study Phase: Phase 3
A Prospective Phase II, Open-Label, Single-arm, Multicenter, Study to Assess Efficacy and Safety of SEG101 (Crizanlizumab), in Sickle Cell Disease Patients With Priapism (SPARTAN)
A Prospective Phase II, Open-Label, Single-arm, Multicenter, Study to Assess Efficacy and Safety of SEG101 (Crizanlizumab), in Sickle Cell Disease Patients With Priapism (SPARTAN)
Enrollment Status: Completed
Publish Date: January 13, 2026
Intervention Type: Drug
Study Drug: Crizanlizumab
Study Phase: Phase 2
LCI-HEM-SCD-ST3P-UP-001: A Comparative Effectiveness Study of Peer Mentoring [PM] Versus Structured Transition Education Based Intervention [STE] for the Management of Care Transitions in Emerging Adults With Sickle Cell Disease (SCD)
LCI-HEM-SCD-ST3P-UP-001: A Comparative Effectiveness Study of Peer Mentoring [PM] Versus Structured Transition Education Based Intervention [STE] for the Management of Care Transitions in Emerging Adults With Sickle Cell Disease (SCD)
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Other
Study Phase: Not Applicable
A Retrospective Data Collection and Analysis Study of Patients With Sickle Cell Disease (SCD) Who Have Been Treated With Oxbryta® (Voxelotor)
A Retrospective Data Collection and Analysis Study of Patients With Sickle Cell Disease (SCD) Who Have Been Treated With Oxbryta® (Voxelotor)
Enrollment Status: Completed
Publish Date: March 06, 2024
Intervention Type: Drug
A Phase II Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients With Sickle Cell Diseases
A Phase II Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients With Sickle Cell Diseases
Enrollment Status: Completed
Publish Date: July 19, 2023
Intervention Type: Drug
Study Drug: Riociguat
Study Phase: Phase 2
A Comparison of Individualized vs. Weight Based Protocols to Treat Vaso-Occlusive Episodes in Sickle Cell Disease
A Comparison of Individualized vs. Weight Based Protocols to Treat Vaso-Occlusive Episodes in Sickle Cell Disease
Enrollment Status: Terminated
Publish Date: July 03, 2023
Intervention Type: Other, Drug
Study Drugs: Morphine, Hydromorphone
Study Phase: Phase 3
View 5 Less Clinical Trials

46 Total Publications

Implicit bias in pain management: The intersection of stigma, race, and chronic disease in sickle cell disease.
Implicit bias in pain management: The intersection of stigma, race, and chronic disease in sickle cell disease.
Journal: Journal of the National Medical Association
Published: October 07, 2025
Similar Doctors
Expertise in
17
conditions
Dr. Ruben A. Mesa
Hematology | Oncology
Expertise in
17
conditions
Dr. Ruben A. Mesa
Hematology | Oncology
Referral required

Atrium Health Levine Cancer Institute

1021 Morehead Medical Drive, 
Charlotte, NC 
 (39.9 miles away)
980-442-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ruben Mesa is a Hematologist and an Oncologist practicing medicine in Charlotte, North Carolina. Dr. Mesa is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Myelofibrosis, Polycythemia Vera, Myeloproliferative Neoplasms (MPN), Bone Marrow Transplant, and Splenectomy. Dr. Mesa is board certified in American Board Of Internal Medicine, Hematology. Dr. Mesa is currently accepting new patients.

Expertise in
11
conditions
Dr. Manisha Bhutani
Hematology | Oncology
Expertise in
11
conditions
Dr. Manisha Bhutani
Hematology | Oncology
Referral may be required

Atrium Health Levine Cancer Institute (Hematology)

1021 Morehead Medical Drive, Building 2, Suite 60201, 
Charlotte, NC 
 (39.9 miles away)
980-442-4363
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Manisha Bhutani is a Hematologist and an Oncologist practicing medicine in Charlotte, North Carolina. Dr. Bhutani is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Bhutani is board certified in American Board Of Internal Medicine and American Board Of Internal Medicine, Hematology. Dr. Bhutani is currently accepting new patients.

Expertise in
12
conditions
Dr. Kathryn F. Mileham
Hematology | Oncology
Expertise in
12
conditions
Dr. Kathryn F. Mileham
Hematology | Oncology
Referral may be required

Atrium Health Levine Cancer Institute (Thoracic-Pulmonary)

1021 Morehead Medical Drive, Building 2, Suite 30500, 
Charlotte, NC 
 (39.9 miles away)
980-442-3300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kathryn Mileham is a Hematologist and an Oncologist practicing medicine in Charlotte, North Carolina. Dr. Mileham is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, EGFR Positive Lung Cancer, and Small Cell Lung Cancer (SCLC). Dr. Mileham is board certified in American Board Of Internal Medicine, Medical Oncology. Dr. Mileham is currently accepting new patients.

Frequently Asked Questions about Dr. Ifeyinwa Osunkwo

How do I make an appointment with Dr. Ifeyinwa Osunkwo?

You can book an appointment with Dr. Ifeyinwa Osunkwo by calling their office at 980-442-2000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ifeyinwa Osunkwo a top-rated expert for Sickle Cell Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ifeyinwa Osunkwo is classified as an Elite expert for Sickle Cell Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ifeyinwa Osunkwo specialize in?

While Dr. Ifeyinwa Osunkwo is a Hematology, they have specific expertise in Sickle Cell Disease, Hemoglobinopathy, and Congenital Hemolytic Anemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Ifeyinwa Osunkwo participate in research or clinical trials?

Yes. Dr. Ifeyinwa Osunkwo has published 46 articles and abstracts on conditions like Sickle Cell Disease. You can view a list of Dr. Ifeyinwa Osunkwo's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ifeyinwa Osunkwo accept my insurance?

Dr. Ifeyinwa Osunkwo accepts most major insurance plans, including Blue Cross Blue Shield and Cigna. We recommend calling the office directly at 980-442-2000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Osunkwo's expertise for a condition
ConditionClose
    View All 7 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile